The EU Commission accepts the commitment offered by a pharmaceutical company for excessive pricing (Aspen)

In February 2021, the European Commission’s (“Commission”) long-running excessive pricing case against Aspen was brought to a close, with Aspen accepting a series of forward-looking pricing and supply commitments, but avoiding any fines or requirements to repay all of the higher prices charged (see VBB on Competition Law, Volume 2021, No. 2). This appears to have been a good result for Aspen, particularly in comparison with the € 5.2 million fine received in the 2016 decision from the Italian competition authority. Against this backdrop, it is

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)

Citation

Michael Clancy, Samuel Hall, The EU Commission accepts the commitment offered by a pharmaceutical company for excessive pricing (Aspen), 10 février 2021, e-Competitions February 2021, Art. N° 100835

Visites 189

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues